Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

NCT06195306 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

66

Enrollment

NIH

Sponsor class

Conditions

Breast Atypical Hyperplasia
Breast Carcinoma
Breast Ductal Carcinoma In Situ
Breast Lobular Carcinoma In Situ

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Mammography
DRUG: Omega-3-Acid Ethyl Esters
OTHER: Questionnaire Administration
PROCEDURE: Random Periareolar Fine-Needle Aspiration
DRUG: Tamoxifen

Sponsor

National Cancer Institute (NCI)